Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
PONTE VEDRA, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced it will highlight new technology innovations and three-year interim ALIGN3D™ clinical results at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference in Tampa, Florida from February 1-4, 2024.
Related news for (TMCI)
- Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results
- 24/7 Market News Snapshot 05 November, 2024 – Treace Medical Concepts, Inc. Common Stock (NASDAQ:TMCI)
- Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
- Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure